NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-09-28 13:32இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Parmax Pharma Reports Major Fire Incident at Hadamtala Plant; 2 Employees Injured
Parmax Pharma reported a major fire accident that occurred at approximately 2:00 a.m. on September 28, 2026, at its plant in Hadamtala, Rajkot, Gujarat. The fire has been controlled, but two employees were injured and hospitalised; no fatal casualties were reported. The company stated that the quantum of loss is currently being assessed and confirmed that damages are covered by insurance. Given the company's micro-cap size (Rs 51 Cr market cap) and negative net worth (-Rs 6 Cr), any plant downtime could materially disrupt operations.
உச்சம் நம்பிக்கை
என்ன மாறியதுA major fire broke out at Parmax Pharma's Hadamtala manufacturing facility, causing injuries to two staff members and property damage.
ஏன் இது முக்கியம்Manufacturing disruptions at the primary plant could affect quarterly production and revenue for a financially leveraged company with TTM revenue of just Rs 18 Cr.
Incident Time: 2:00 a.m. on September 28, 2026Injuries Reported: 2Fatal Casualties: 0Quantum of Loss: வெளியிடப்படவில்லை
📅 குறுகிய காலம்Expect potential operational delays, temporary factory downtime, and inventory write-offs pending insurance survey and claims processing.
📈 நீண்ட காலம்Prolonged plant disruption could impact revenue turnaround efforts, given negative operating cash flows and negative net worth of Rs -6 Cr.
⚠ அபாய எச்சரிக்கைகள்
Operational disruption and factory downtime
Unquantified asset and inventory damage
Delay or shortfall in insurance claim settlement
👀 கவனிக்க வேண்டியவை
Monitor subsequent exchange disclosures regarding the assessed financial damage, insurance claim settlements, and the operational shutdown or restart timeline of the plant.
Parmax Pharma Allots Shares and Warrants to Raise Up to ₹19.28 Cr on Preferential Basis
Parmax Pharma has approved the allotment of 31,37,586 equity shares at ₹36.50 per share, raising ₹11.45 Cr immediately. The board also allotted 21,45,145 convertible warrants at ₹36.50 each (convertible within 18 months), adding a potential ₹7.83 Cr. The total potential raise of ₹19.28 Cr compares to a market cap of ₹49 Cr (~39%) and TTM revenue of ₹18 Cr (~107%). Several allottees, including Managing Director Umang Gosalia, are shifting to the Promoter/Promoter Group classification.
உச்சம் நம்பிக்கை
என்ன மாறியதுBoard executed the allotment of 31.38 lakh equity shares and 21.45 lakh convertible warrants on a preferential basis following in-principle stock exchange approval received on August 21, 2026.
ஏன் இது முக்கியம்The ₹11.45 Cr immediate equity infusion provides critical capital to a company with negative net worth (-₹6 Cr) and ₹12 Cr in debt, strengthening its balance sheet.
Equity shares allotted: 31,37,586Immediate equity fundraise: ₹11.45 கோடிConvertible warrants allotted: 21,45,145Issue price per share/warrant: ₹36.50Immediate fundraise vs TTM revenue: ~63.6%Total potential fundraise vs Market Cap: ~39.3%
📅 குறுகிய காலம்Positive for solvency and working capital, though the allotment price of ₹36.50 is at a sharp discount to the current market price of ₹131.20, creating dilution risk.
📈 நீண்ட காலம்Significantly alters the ownership structure and aids turnaround efforts by restoring positive net worth if operational turnaround sustains.
⚠ அபாய எச்சரிக்கைகள்
Substantial equity dilution at ₹36.50 vs current market price of ₹131.20
Negative historical net worth (-₹6 Cr) and persistent annual losses prior to Q1 FY27
👀 கவனிக்க வேண்டியவை
Track receipt of listing/trading approvals on BSE for the newly allotted shares, and watch for subsequent warrant conversion notices and debt repayment or capex deployments.
Parmax Pharma: Acquirers to Take Over 30.80% Stake and Reclassify as New Promoters
Parmax Pharma has announced a proposed change in promoter classification following an Open Offer and a Share Purchase Agreement dated June 08, 2026. Acquirers Dhiren Chandulal Shah, Sunil Chinubhai Shah, and PACs have agreed to acquire 11,52,450 equity shares (30.80% of equity share capital) from erstwhile promoters Alkesh Gopani, Vipul Gopani, and Pravina Gopani. Upon completion of share transfers and open offer formalities, the incoming acquirers and PACs will be classified as Promoters and Promoter Group, while the selling promoters will be reclassified under the public category.
உச்சம் நம்பிக்கை
என்ன மாறியதுFormal intimation to stock exchanges regarding the proposed reclassification of erstwhile promoters to public status and induction of incoming acquirers as new promoters.
ஏன் இது முக்கியம்A complete change in promoter control brings new management to a financially distressed entity (negative net worth of ₹-6 Cr and TTM PAT of ₹-1 Cr), potentially triggering strategic restructuring.
Shares to be acquired: 11,52,450Stake size: 30.80%SPA Date: ஜூன் 08, 2026Alkesh Gopani Holding: 17.92%Vipul Gopani Holding: 12.87%
📅 குறுகிய காலம்Short-term market sentiment is likely to reflect optimism over leadership change, though regulatory filings and stock exchange approvals for reclassification will take time to conclude.
📈 நீண்ட காலம்Crucial for long-term survival and growth; new promoters will need to address the company's negative net worth, debt obligations, and operational turnaround.
⚠ அபாய எச்சரிக்கைகள்
Turnaround and execution risk under new management
Company has negative net worth (₹-6 Cr) and ongoing annual operating losses
👀 கவனிக்க வேண்டியவை
Track the final closure and settlement of the open offer, subsequent share transfer filings, and any strategic turnaround or capital infusion plans outlined by the incoming management.
Parmax Pharma Gets BSE Nod for ~Rs 19.3 Cr Preferential Issue of Shares and Warrants
Parmax Pharma received in-principle approval from BSE for its proposed preferential issue of up to 31,37,586 equity shares and 21,45,145 convertible warrants at a minimum price of Rs 36.50 each. The total potential capital infusion is approximately Rs 19.28 crore, which exceeds the company's TTM revenue of Rs 18 crore. This capital injection is crucial given the company's negative net worth of Rs -6 crore and debt of Rs 12 crore. However, the issue price of Rs 36.50 represents a steep discount to the current market price of Rs 127.4.
உச்சம் நம்பிக்கை
என்ன மாறியதுBSE has granted regulatory in-principle approval for preferential allotment of 52.83 lakh equity shares and warrants.
ஏன் இது முக்கியம்The ~Rs 19.28 Cr capital infusion can help repair the negative net worth (Rs -6 Cr) and reduce debt (Rs 12 Cr), although it implies significant equity dilution.
Equity shares to be issued: 31,37,586Warrants to be issued: 21,45,145Minimum issue price: Rs 36.50 per share/warrantTotal potential fundraise: ~Rs 19.28 CrFundraise vs TTM Revenue: ~107%
📅 குறுகிய காலம்Receipt of in-principle approval paves the way for formal allotment and cash inflows in the coming weeks.
📈 நீண்ட காலம்Infusion of fresh equity capital is structurally vital for stabilizing operations and turning net worth positive, provided operational turnaround follows.
⚠ அபாய எச்சரிக்கைகள்
Substantial equity dilution for existing shareholders
Preferential issue price of Rs 36.50 is significantly below current market price of Rs 127.4
👀 கவனிக்க வேண்டியவை
Track the completion of allotment, receipt of funds, and subsequent listing approval, alongside monitor how proceeds are deployed toward debt reduction or working capital.
Q1 PAT Turns Positive to Rs 2.20 Cr on Rs 8.22 Cr Revenue; Board Reconstituted with New Chairman
Parmax Pharma reported Q1 FY27 revenue from operations of Rs 8.22 Cr (Rs 82,209.52 thousand), up 323% YoY from Rs 1.94 Cr in Q1 FY26 and representing ~68% of its entire FY26 revenue. Net profit turned positive to Rs 2.20 Cr (EPS Rs 5.88) compared to a loss of Rs 0.76 Cr in the year-ago quarter, heavily aided by a one-off insurance claim settlement of Rs 2.07 Cr. The company also reconstituted its board, appointing Mr. Dhiren Chandulal Shah as Chairman and Additional Director alongside other director appointments.
உச்சம் நம்பிக்கை
என்ன மாறியதுReported strong Q1 operational turnaround with Rs 8.22 Cr revenue and appointed a new Chairman alongside three other directors.
ஏன் இது முக்கியம்Top-line expansion indicates operational recovery, though bottom-line profit was heavily boosted by non-recurring insurance proceeds; the new leadership team must sustain operational stability to address negative net worth (-Rs 6 Cr).
📅 குறுகிய காலம்Market may react positively to the substantial top-line surge and headline profit, though gains should be assessed net of the one-off insurance settlement.
📈 நீண்ட காலம்Long-term recovery hinges on sustaining core profitability, addressing historical debt (Rs 12 Cr), and reversing negative net worth.
⚠ அபாய எச்சரிக்கைகள்
One-off insurance settlement of Rs 2.07 Cr accounted for majority of reported Q1 profit.
Company omitted depreciation on the effluent treatment plant during the quarter.
Negative net worth of -Rs 6 Cr with elevated historical debt levels.
👀 கவனிக்க வேண்டியவை
Track core operational margins in upcoming quarters after stripping out the Rs 2.07 Cr one-off insurance gain, and monitor shareholder voting on director appointments at the ensuing AGM.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Q1 Revenue Surges 323% YoY to Rs 8.22 Cr; Net Profit at Rs 2.20 Cr Aided by Insurance Claim
Parmax Pharma reported a sharp top-line turnaround for Q1 ended June 30, 2026, with revenue from operations rising 323% YoY to Rs 8.22 Cr compared to Rs 1.94 Cr in Q1 FY26. Net profit stood at Rs 2.20 Cr against a net loss of Rs 0.76 Cr in the year-ago period, resulting in a quarterly EPS of Rs 5.88. Profitability was significantly boosted by a one-time insurance claim settlement of Rs 2.07 Cr accounted under other income. Concurrently, the company appointed Mr. Dhiren Chandulal Shah as Additional Director and Chairman.
உச்சம் நம்பிக்கை
என்ன மாறியதுParmax Pharma reported strong revenue growth and turned profitable in Q1, alongside restructuring its Board of Directors with a new Chairman.
ஏன் இது முக்கியம்Quarterly sales of Rs 8.22 Cr represent ~45.7% of previous TTM revenue, providing operational scale to a microcap company with historic negative net worth.
Revenue from operations (Q1): Rs 8.22 கோடிNet Profit (Q1): Rs 2.20 கோடிInsurance claim in Other Income: Rs 2.07 கோடிQ1 வருவாய் vs TTM வருவாய்: ~45.7%Basic EPS: Rs 5.88
📅 குறுகிய காலம்Turnaround in headline revenue and net profitability is likely to be viewed favorably, though gains will be weighed against the non-recurring insurance component.
📈 நீண்ட காலம்Long-term viability hinges on sustaining core pharma operating margins and repairing the negative net worth without relying on exceptional items.
⚠ அபாய எச்சரிக்கைகள்
Net profit of Rs 2.20 Cr is predominantly driven by a non-recurring Rs 2.07 Cr insurance claim settlement
Auditor notes indicate the company did not charge depreciation on the effluent treatment plant during the quarter
Balance sheet context shows negative net worth (-Rs 6 Cr)
58.01% Stake: Sunil Shah & Others Acquire 11.52 Lakh Shares in Parmax Pharma
A group of acquirers led by Dhiren Chandulal Shah and Sunil Chinubhai Shah has completed the acquisition of 11,52,450 equity shares (approx. 30.8% stake) at Rs 35.00 per share. This off-market transaction, executed on August 13, 2026, follows a Share Purchase Agreement dated June 08, 2026. Post-acquisition, the total shareholding of the acquirer group has increased from 27.20% to 58.01%, marking a formal change in control. The acquisition price of Rs 35 is significantly lower than the current market price of Rs 113.2, reflecting the distressed financial state of the company.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe majority ownership and control of Parmax Pharma have shifted to a new promoter group (Shah and associates), who now hold 58.01% of the equity.
ஏன் இது முக்கியம்For a micro-cap company with a market cap of only Rs 42 Cr and negative net worth, a change in control is a major event that could potentially lead to a business turnaround or restructuring.
Shares Acquired: 11,52,450Acquisition Price: Rs 35.00Post-Acquisition Stake: 58.01%Deal Value vs TTM Revenue: ~33.3%Current Market Price: Rs 113.2
📅 குறுகிய காலம்The stock has seen a massive 263% return in 3 months; the completion of the takeover at a lower price (Rs 35) may lead to price consolidation or volatility as the market assesses the new leadership.
📈 நீண்ட காலம்The long-term outlook depends entirely on the new promoters' ability to reverse the consistent losses (FY26 PAT of Rs -4.16 Cr) and manage the Rs 12 Cr debt on a negative net worth base.
⚠ அபாய எச்சரிக்கைகள்
Negative net worth of Rs -6 Cr
Significant gap between acquisition price (Rs 35) and market price (Rs 113.2)
High debt-to-equity ratio due to eroded capital
👀 கவனிக்க வேண்டியவை
Monitor the new management's plan to address the company's negative net worth of Rs -6 Cr and operational losses. Investors should watch for any capital infusion or strategic shifts aimed at improving the -29.6% operating margins.
26% Open Offer for Parmax Pharma: Pre-Offer Advertisement Published by Acquirers
Acquirers Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with 10 Persons Acting in Concert (PACs), have published the pre-offer advertisement for an open offer to acquire up to 23,46,250 shares of Parmax Pharma. This represents 26.00% of the expanded voting share capital. The company is currently in a precarious financial position with a negative net worth of ₹6 Cr and a TTM loss of ₹4 Cr. This open offer is a critical step in a potential change of control or significant stake consolidation.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe open offer process has reached the formal public advertisement stage, signaling the start of the tendering period for public shareholders.
ஏன் இது முக்கியம்With the company facing significant financial distress (negative net worth and consistent losses), a change in the controlling group or a major stake acquisition is the most significant event for its potential survival or turnaround.
Shares under Open Offer: 23,46,250Stake Percentage: 26.00%TTM வருவாய்: ₹12 கோடிNet Worth: ₹-6 கோடிகடன்: ₹12 கோடி
📅 குறுகிய காலம்The stock price may align closely with the open offer price in the coming weeks as the tendering period approaches.
📈 நீண்ட காலம்The long-term outlook depends on the acquirers' ability to infuse capital and restructure operations to reverse the current negative OPM of -29.6%.
⚠ அபாய எச்சரிக்கைகள்
Negative Net Worth
Consistent Operating Losses
High Debt-to-Equity ratio
Potential for low liquidity during the offer period
👀 கவனிக்க வேண்டியவை
Investors should monitor the specific offer price and the letter of offer for details on the acquirers' future plans for the company, given its negative net worth and -83% ROCE.
26% Open Offer: Independent Directors Issue Recommendations for Parmax Pharma
The Committee of Independent Directors (IDC) of Parmax Pharma has published its recommendations regarding the open offer by Dhiren Chandulal Shah and Sunil Chinubhai Shah. The offer seeks to acquire up to 23,46,250 equity shares, representing 26% of the expanded voting share capital. This comes at a time when the company is financially distressed, reporting a negative net worth of Rs -6 Cr and TTM losses of Rs -4 Cr. The stock has seen a significant 231.7% price return over the last three months despite these weak fundamentals.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe Independent Directors have formally issued their mandatory regulatory opinion on the fairness of the ongoing open offer.
ஏன் இது முக்கியம்This is a critical step in a potential change of control or significant stake increase for a loss-making company with negative equity, which may impact future business strategy.
📅 குறுகிய காலம்The stock may see volatility as investors digest the IDC's view on whether the offer price is reasonable compared to the current market price.
📈 நீண்ட காலம்The outcome of the open offer will determine the new shareholding structure and potential for a turnaround in this currently loss-making pharmaceutical entity.
⚠ அபாய எச்சரிக்கைகள்
Negative net worth of Rs -6 Cr
Consistent quarterly losses (Rs -0.58 Cr in Mar 2026)
High debt of Rs 12 Cr relative to market cap
👀 கவனிக்க வேண்டியவை
Investors should read the full IDC recommendation in the July 27, 2026, editions of Financial Express or Jansatta to evaluate the fairness of the offer price before the tendering period.
₹42.80 Open Offer for 26% Stake in Parmax Pharma by New Acquirers
Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with 10 PACs, have issued a Letter of Offer to acquire a 26% stake in Parmax Pharma. The offer price is set at ₹42.80 per share, which represents a significant ~58% discount to the current market price of ₹102.9. This acquisition follows a proposed preferential issue and targets 23,46,250 shares of the expanded voting capital. The company is currently in financial distress with a negative net worth of ₹-6 Cr and a TTM loss of ₹4 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுA group of new acquirers has formalized an open offer to take a significant 26% stake in the company following a planned preferential share issuance.
ஏன் இது முக்கியம்This represents a potential change in control or significant capital infusion for a micro-cap company that is currently loss-making and has eroded its entire net worth.
Offer Price: ₹42.80Current Market Price: ₹102.9Offer Size (Shares): 23,46,250Offer vs CMP Discount: ~58.4%TTM Net Profit: ₹-4 கோடிNet Worth: ₹-6 கோடி
📅 குறுகிய காலம்The stock may experience volatility as the market reacts to the low offer price versus the recent 213% three-month price surge.
📈 நீண்ட காலம்The long-term outlook depends entirely on the new management's ability to turnaround a company with negative net worth and consistent operating losses.
⚠ அபாய எச்சரிக்கைகள்
Negative net worth of ₹-6 Cr
Offer price is at a massive discount to market price
High debt-to-equity concerns
Consistent quarterly losses
👀 கவனிக்க வேண்டியவை
Monitor the progress of the preferential issue and the official tendering dates; however, the offer price is unlikely to be attractive for retail investors given it is ~58% below current market levels.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
